DAH2DanielHaberDaniel Arie Haber, M.D., Ph.D.42.37730000000000-71.0525000000000010825Haber, DanielArie617/726-7805Kurt J. Isselbacher Professor of Oncologycatalyst:advisorInMentoringCompletedStudentProjectcompleted student projectscatalyst:eCommonsLogineCommons LoginMentoring - Completed Student Projectprns:coAuthorOfcoauthor ofprns:endDateend dateFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:principalInvestigatorNameprincipal investigator nameprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:startDatestart dateprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:address2address line 2vivo:address3address line 3vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionGrantvivo:hasResearchArearesearch areasvivo:hasResearcherRoleresearch activitiesvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:middleNamemiddle name or initialvivo:overviewoverviewvivo:personInPositionpositionsvivo:phoneNumberphonePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleResearcher Rolevivo:researcherRoleOfresearcher role ofvivo:roleContributesTocontributes tovivo:sponsorAwardIdsponsor award idrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson11301010Cantor SB, Bell DW, Ganesan S, Kass EM, Drapkin R, Grossman S, Wahrer DC, Sgroi DC, Lane WS, Haber DA, Livingston DMCellBACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell. 2001 Apr 06; 105(1):149-60.Cell2001-04-06T00:00:002001BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function.10617473Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DAScience (New York, N.Y.)Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science. 1999 Dec 24; 286(5449):2528-31.Science1999-12-24T00:00:001999Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.11278547Wang W, Lee SB, Palmer R, Ellisen LW, Haber DAThe Journal of biological chemistryA functional interaction with CBP contributes to transcriptional activation by the Wilms tumor suppressor WT1. J Biol Chem. 2001 May 18; 276(20):16810-6.J Biol Chem2001-02-13T00:00:002001A functional interaction with CBP contributes to transcriptional activation by the Wilms tumor suppressor WT1.6671816Haber DInternational journal of aging & human developmentYoga as a preventive health care program for white and black elders: an exploratory study. Int J Aging Hum Dev. 1983; 17(3):169-76.Int J Aging Hum Dev1983-01-01T00:00:001983Yoga as a preventive health care program for white and black elders: an exploratory study.8387453Skare J, Wu BL, Madan S, Pulijaal V, Purtilo D, Haber D, Nelson D, Sylla B, Grierson H, Nitowsky HGenomicsCharacterization of three overlapping deletions causing X-linked lymphoproliferative disease. Genomics. 1993 Apr; 16(1):254-5.Genomics1993-04-01T00:00:001993Characterization of three overlapping deletions causing X-linked lymphoproliferative disease.9544888Nichols KE, Li FP, Haber DA, Diller LThe Journal of pediatricsChildhood cancer predisposition: applications of molecular testing and future implications. J Pediatr. 1998 Mar; 132(3 Pt 1):389-97.J Pediatr1998-03-01T00:00:001998Childhood cancer predisposition: applications of molecular testing and future implications.18523561Li H, Smolen GA, Beers LF, Xia L, Gerald W, Wang J, Haber DA, Lee SBPloS oneAdenosine transporter ENT4 is a direct target of EWS/WT1 translocation product and is highly expressed in desmoplastic small round cell tumor. PLoS One. 2008 Jun 04; 3(6):e2353.PLoS One2008-06-04T00:00:002008Adenosine transporter ENT4 is a direct target of EWS/WT1 translocation product and is highly expressed in desmoplastic small round cell tumor.18559533Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman JCancer researchElevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res. 2008 Jun 15; 68(12):4853-61.Cancer Res2008-06-15T00:00:002008Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma.1673293Huff V, Miwa H, Haber DA, Call KM, Housman D, Strong LC, Saunders GFAmerican journal of human geneticsEvidence for WT1 as a Wilms tumor (WT) gene: intragenic germinal deletion in bilateral WT. Am J Hum Genet. 1991 May; 48(5):997-1003.Am J Hum Genet1991-05-01T00:00:001991Evidence for WT1 as a Wilms tumor (WT) gene: intragenic germinal deletion in bilateral WT.12604796Paulding CA, Ruvolo M, Haber DAProceedings of the National Academy of Sciences of the United States of AmericaThe Tre2 (USP6) oncogene is a hominoid-specific gene. Proc Natl Acad Sci U S A. 2003 Mar 04; 100(5):2507-11.Proc Natl Acad Sci U S A2003-02-25T00:00:002003The Tre2 (USP6) oncogene is a hominoid-specific gene.18980981Chin TM, Quinlan MP, Singh A, Sequist LV, Lynch TJ, Haber DA, Sharma SV, Settleman JClinical cancer research : an official journal of the American Association for Cancer ResearchReduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment. Clin Cancer Res. 2008 Nov 01; 14(21):6867-76.Clin Cancer Res2008-11-01T00:00:002008Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.19651985Yu M, Smolen GA, Zhang J, Wittner B, Schott BJ, Brachtel E, Ramaswamy S, Maheswaran S, Haber DAGenes & developmentA developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression. Genes Dev. 2009 Aug 01; 23(15):1737-42.Genes Dev2009-08-01T00:00:002009A developmentally regulated inducer of EMT, LBX1, contributes to breast cancer progression.20432502Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, Haber DA, Louis DN, Ellisen LW, Borger DR, Iafrate AJEMBO molecular medicineRapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010 May; 2(5):146-58.EMBO Mol Med2010-05-01T00:00:002010Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine.Authorship 10312223093251Miyamoto DT, Lee RJ, Stott SL, Ting DT, Wittner BS, Ulman M, Smas ME, Lord JB, Brannigan BW, Trautwein J, Bander NH, Wu CL, Sequist LV, Smith MR, Ramaswamy S, Toner M, Maheswaran S, Haber DACancer discoveryAndrogen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov. 2012 Nov; 2(11):995-1003.Cancer Discov2012-10-23T00:00:002012Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer.2023-04-30HABER, DANIEL A.;MAHESWARAN, SHYAMALA ;TONER, MEHMET2018-05-08Metastasis and biophysics of clusters of circulating tumor cells in the microcirculationU01CA21429717285735Sequist LV, Joshi VA, Jänne PA, Muzikansky A, Fidias P, Meyerson M, Haber DA, Kucherlapati R, Johnson BE, Lynch TJThe oncologistResponse to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist. 2007 Jan; 12(1):90-8.Oncologist2007-01-01T00:00:002007Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.16488990Kwak EL, Kim S, Zhang J, Cardiff RD, Schmidt EV, Haber DACancer researchMammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant. Cancer Res. 2006 Feb 15; 66(4):1923-8.Cancer Res2006-02-15T00:00:002006Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant.12202036Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, Haber D, Hariharan IKCellsalvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell. 2002 Aug 23; 110(4):467-78.Cell2002-08-23T00:00:002002salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines.12453409Ellisen LW, Ramsayer KD, Johannessen CM, Yang A, Beppu H, Minda K, Oliner JD, McKeon F, Haber DAMolecular cellREDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species. Mol Cell. 2002 Nov; 10(5):995-1005.Mol Cell2002-11-01T00:00:002002REDD1, a developmentally regulated transcriptional target of p63 and p53, links p63 to regulation of reactive oxygen species.14651841Haber DACellThe BRCA2-EMSY connection: implications for breast and ovarian tumorigenesis. Cell. 2003 Nov 26; 115(5):507-8.Cell2003-11-26T00:00:002003The BRCA2-EMSY connection: implications for breast and ovarian tumorigenesis.22341439Singh A, Sweeney MF, Yu M, Burger A, Greninger P, Benes C, Haber DA, Settleman JCellTAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell. 2012 Feb 17; 148(4):639-50.Cell2012-02-17T00:00:002012TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.16585167Smolen GA, Muir B, Mohapatra G, Barmettler A, Kim WJ, Rivera MN, Haserlat SM, Okimoto RA, Kwak E, Dahiya S, Garber JE, Bell DW, Sgroi DC, Chin L, Deng CX, Haber DACancer researchFrequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis. Cancer Res. 2006 Apr 01; 66(7):3452-5.Cancer Res2006-04-01T00:00:002006Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis.16894141Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, Deng CX, Brugge JS, Haber DAProceedings of the National Academy of Sciences of the United States of AmericaTransforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A. 2006 Aug 15; 103(33):12405-10.Proc Natl Acad Sci U S A2006-08-07T00:00:002006Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon.10555141Okano M, Bell DW, Haber DA, Li ECellDNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999 Oct 29; 99(3):247-57.Cell1999-10-29T00:00:001999DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development.12011077Andrews HN, Mullan PB, McWilliams S, Sebelova S, Quinn JE, Gilmore PM, McCabe N, Pace A, Koller B, Johnston PG, Haber DA, Harkin DPThe Journal of biological chemistryBRCA1 regulates the interferon gamma-mediated apoptotic response. J Biol Chem. 2002 Jul 19; 277(29):26225-32.J Biol Chem2002-05-13T00:00:002002BRCA1 regulates the interferon gamma-mediated apoptotic response.12842911Lee BC, Cheng T, Adams GB, Attar EC, Miura N, Lee SB, Saito Y, Olszak I, Dombkowski D, Olson DP, Hancock J, Choi PS, Haber DA, Luster AD, Scadden DTGenes & developmentP2Y-like receptor, GPR105 (P2Y14), identifies and mediates chemotaxis of bone-marrow hematopoietic stem cells. Genes Dev. 2003 Jul 01; 17(13):1592-604.Genes Dev2003-07-01T00:00:002003P2Y-like receptor, GPR105 (P2Y14), identifies and mediates chemotaxis of bone-marrow hematopoietic stem cells.8047084Coppes MJ, Haber DA, Grundy PEThe New England journal of medicineGenetic events in the development of Wilms' tumor. N Engl J Med. 1994 Sep 01; 331(9):586-90.N Engl J Med1994-09-01T00:00:001994Genetic events in the development of Wilms' tumor.20930119Stott SL, Hsu CH, Tsukrov DI, Yu M, Miyamoto DT, Waltman BA, Rothenberg SM, Shah AM, Smas ME, Korir GK, Floyd FP, Gilman AJ, Lord JB, Winokur D, Springer S, Irimia D, Nagrath S, Sequist LV, Lee RJ, Isselbacher KJ, Maheswaran S, Haber DA, Toner MProceedings of the National Academy of Sciences of the United States of AmericaIsolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A. 2010 Oct 26; 107(43):18392-7.Proc Natl Acad Sci U S A2010-10-07T00:00:002010Isolation of circulating tumor cells using a microvortex-generating herringbone-chip.20979469Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJThe New England journal of medicineAnaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703.N Engl J Med2010-10-28T00:00:002010Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.21458664Haber DA, Gray NS, Baselga JCellThe evolving war on cancer. Cell. 2011 Apr 01; 145(1):19-24.Cell2011-04-01T00:00:002011The evolving war on cancer.15193263Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, Tran D, Tassin A, Amon P, Wang W, Wang W, Enright E, Stecker K, Estepa-Sabal E, Smith B, Younger J, Balis U, Michaelson J, Bhan A, Habin K, Baer TM, Brugge J, Haber DA, Erlander MG, Sgroi DCCancer cellA two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004 Jun; 5(6):607-16.Cancer Cell2004-06-01T00:00:002004A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.16818680Bell DW, Haber DAClinical cancer research : an official journal of the American Association for Cancer ResearchA blood-based test for epidermal growth factor receptor mutations in lung cancer. Clin Cancer Res. 2006 Jul 01; 12(13):3875-7.Clin Cancer Res2006-07-01T00:00:002006A blood-based test for epidermal growth factor receptor mutations in lung cancer.17097564Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y, Classon M, Haber DA, Settleman JCancer cellA common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell. 2006 Nov; 10(5):425-35.Cancer Cell2006-11-01T00:00:002006A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes.2154335Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, Rose EA, Kral A, Yeger H, Lewis WHCellIsolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell. 1990 Feb 09; 60(3):509-20.Cell1990-02-09T00:00:001990Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus.17318210Sharma SV, Bell DW, Settleman J, Haber DANature reviews. CancerEpidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007 Mar; 7(3):169-81.Nat Rev Cancer2007-03-01T00:00:002007Epidermal growth factor receptor mutations in lung cancer.17721994Bell DW, Kim SH, Godwin AK, Schiripo TA, Harris PL, Haserlat SM, Wahrer DC, Haiman CA, Daly MB, Niendorf KB, Smith MR, Sgroi DC, Garber JE, Olopade OI, Le Marchand L, Henderson BE, Altshuler D, Haber DA, Freedman MLInternational journal of cancerGenetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer. 2007 Dec 15; 121(12):2661-7.Int J Cancer2007-12-15T00:00:002007Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.20569696Aiden AP, Rivera MN, Rheinbay E, Ku M, Coffman EJ, Truong TT, Vargas SO, Lander ES, Haber DA, Bernstein BECell stem cellWilms tumor chromatin profiles highlight stem cell properties and a renal developmental network. Cell Stem Cell. 2010 Jun 04; 6(6):591-602.Cell Stem Cell2010-06-04T00:00:002010Wilms tumor chromatin profiles highlight stem cell properties and a renal developmental network.20639869Ozsolak F, Ting DT, Wittner BS, Brannigan BW, Paul S, Bardeesy N, Ramaswamy S, Milos PM, Haber DANature methodsAmplification-free digital gene expression profiling from minute cell quantities. Nat Methods. 2010 Aug; 7(8):619-21.Nat Methods2010-07-18T00:00:002010Amplification-free digital gene expression profiling from minute cell quantities.16818686Jackman DM, Yeap BY, Sequist LV, Lindeman N, Holmes AJ, Joshi VA, Bell DW, Huberman MS, Halmos B, Rabin MS, Haber DA, Lynch TJ, Meyerson M, Johnson BE, Jänne PAClinical cancer research : an official journal of the American Association for Cancer ResearchExon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res. 2006 Jul 01; 12(13):3908-14.Clin Cancer Res2006-07-01T00:00:002006Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.8402654Park S, Tomlinson G, Nisen P, Haber DACancer researchAltered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor. Cancer Res. 1993 Oct 15; 53(20):4757-60.Cancer Res1993-10-15T00:00:001993Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor.18083100Diederichs S, Haber DACellDual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Cell. 2007 Dec 14; 131(6):1097-108.Cell2007-12-14T00:00:002007Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression.2481261Haber DA, Housman DENucleic acids researchMspI/HpaII polymorphism in the human multidrug resistance gene 1. Nucleic Acids Res. 1989 Dec 11; 17(23):10142.Nucleic Acids Res1989-12-11T00:00:001989MspI/HpaII polymorphism in the human multidrug resistance gene 1.20215515Rothenberg SM, Mohapatra G, Rivera MN, Winokur D, Greninger P, Nitta M, Sadow PM, Sooriyakumar G, Brannigan BW, Ulman MJ, Perera RM, Wang R, Tam A, Ma XJ, Erlander M, Sgroi DC, Rocco JW, Lingen MW, Cohen EE, Louis DN, Settleman J, Haber DACancer researchA genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers. Cancer Res. 2010 Mar 15; 70(6):2158-64.Cancer Res2010-03-09T00:00:002010A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.22285752Kim WJ, Rivera MN, Coffman EJ, Haber DAMolecular cellThe WTX tumor suppressor enhances p53 acetylation by CBP/p300. Mol Cell. 2012 Mar 09; 45(5):587-97.Mol Cell2012-01-26T00:00:002012The WTX tumor suppressor enhances p53 acetylation by CBP/p300.18413800Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J, Maheswaran S, Settleman J, Haber DAMolecular cancer therapeuticsThe T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther. 2008 Apr; 7(4):874-9.Mol Cancer Ther2008-04-01T00:00:002008The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.18483364Wittner BS, Sgroi DC, Ryan PD, Bruinsma TJ, Glas AM, Male A, Dahiya S, Habin K, Bernards R, Haber DA, Van't Veer LJ, Ramaswamy SClinical cancer research : an official journal of the American Association for Cancer ResearchAnalysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res. 2008 May 15; 14(10):2988-93.Clin Cancer Res2008-05-15T00:00:002008Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.18593984Bell DW, Brannigan BW, Matsuo K, Finkelstein DM, Sordella R, Settleman J, Mitsudomi T, Haber DAClinical cancer research : an official journal of the American Association for Cancer ResearchIncreased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms. Clin Cancer Res. 2008 Jul 01; 14(13):4079-84.Clin Cancer Res2008-07-01T00:00:002008Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms.Authorship 1065884Authorship 1235561622460902Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, Chen L, Milano RJ, Bignell GR, Tam AT, Davies H, Stevenson JA, Barthorpe S, Lutz SR, Kogera F, Lawrence K, McLaren-Douglas A, Mitropoulos X, Mironenko T, Thi H, Richardson L, Zhou W, Jewitt F, Zhang T, O'Brien P, Boisvert JL, Price S, Hur W, Yang W, Deng X, Butler A, Choi HG, Chang JW, Baselga J, Stamenkovic I, Engelman JA, Sharma SV, Delattre O, Saez-Rodriguez J, Gray NS, Settleman J, Futreal PA, Haber DA, Stratton MR, Ramaswamy S, McDermott U, Benes CHNatureSystematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012 Mar 28; 483(7391):570-5.Nature2012-03-28T00:00:002012Systematic identification of genomic markers of drug sensitivity in cancer cells.17620295Han M, Rivera MN, Batten JM, Haber DA, Dal Cin P, Iafrate AJGenes, chromosomes & cancerWilms' tumor with an apparently balanced translocation t(X;18) resulting in deletion of the WTX gene. Genes Chromosomes Cancer. 2007 Oct; 46(10):909-13.Genes Chromosomes Cancer2007-10-01T00:00:002007Wilms' tumor with an apparently balanced translocation t(X;18) resulting in deletion of the WTX gene.558052Haber DA, Fox DA, Dynan WS, Thilly WGCancer researchCell density dependence of focus formation in the C3H/10T1/2 transformation assay. Cancer Res. 1977 Jun; 37(6):1644-8.Cancer Res1977-06-01T00:00:001977Cell density dependence of focus formation in the C3H/10T1/2 transformation assay.20071161Maheswaran S, Haber DACurrent opinion in genetics & developmentCirculating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev. 2010 Feb; 20(1):96-9.Curr Opin Genet Dev2010-01-12T00:00:002010Circulating tumor cells: a window into cancer biology and metastasis.20424012Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, Inserra EJ, Ulman M, Springer S, Nakamura Z, Moore AL, Tsukrov DI, Kempner ME, Dahl DM, Wu CL, Iafrate AJ, Smith MR, Tompkins RG, Sequist LV, Toner M, Haber DA, Maheswaran SScience translational medicineIsolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med. 2010 Mar 31; 2(25):25ra23.Sci Transl Med2010-03-31T00:00:002010Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer.23180760Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR, Ramaswamy S, Futreal PA, Haber DA, Stratton MR, Benes C, McDermott U, Garnett MJNucleic acids researchGenomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013 Jan; 41(Database issue):D955-61.Nucleic Acids Res2012-11-23T00:00:002012Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.8591961Grundy P, Coppes MJ, Haber DHematology/oncology clinics of North AmericaMolecular genetics of Wilms tumor. Hematol Oncol Clin North Am. 1995 Dec; 9(6):1201-15.Hematol Oncol Clin North Am1995-12-01T00:00:001995Molecular genetics of Wilms tumor.7657166Maheswaran S, Englert C, Bennett P, Heinrich G, Haber DAGenes & developmentThe WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev. 1995 Sep 01; 9(17):2143-56.Genes Dev1995-09-01T00:00:001995The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis.15118073Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DAThe New England journal of medicineActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004 May 20; 350(21):2129-39.N Engl J Med2004-04-29T00:00:002004Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.16857816Sharma SV, Fischbach MA, Haber DA, Settleman JClinical cancer research : an official journal of the American Association for Cancer Research"Oncogenic shock": explaining oncogene addiction through differential signal attenuation. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4392s-4395s.Clin Cancer Res2006-07-15T00:00:002006"Oncogenic shock": explaining oncogene addiction through differential signal attenuation.18077425McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman JProceedings of the National Academy of Sciences of the United States of AmericaIdentification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):19936-41.Proc Natl Acad Sci U S A2007-12-06T00:00:002007Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.Authorship 116762921930940Chiba N, Comaills V, Shiotani B, Takahashi F, Shimada T, Tajima K, Winokur D, Hayashida T, Willers H, Brachtel E, Vivanco MD, Haber DA, Zou L, Maheswaran SProceedings of the National Academy of Sciences of the United States of AmericaHomeobox B9 induces epithelial-to-mesenchymal transition-associated radioresistance by accelerating DNA damage responses. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2760-5.Proc Natl Acad Sci U S A2011-09-19T00:00:002011Homeobox B9 induces epithelial-to-mesenchymal transition-associated radioresistance by accelerating DNA damage responses.Authorship 10999767588596Englert C, Hou X, Maheswaran S, Bennett P, Ngwu C, Re GG, Garvin AJ, Rosner MR, Haber DAThe EMBO journalWT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis. EMBO J. 1995 Oct 02; 14(19):4662-75.EMBO J1995-10-02T00:00:001995WT1 suppresses synthesis of the epidermal growth factor receptor and induces apoptosis.1331933Baird PN, Groves N, Haber DA, Housman DE, Cowell JKOncogeneIdentification of mutations in the WT1 gene in tumours from patients with the WAGR syndrome. Oncogene. 1992 Nov; 7(11):2141-9.Oncogene1992-11-01T00:00:001992Identification of mutations in the WT1 gene in tumours from patients with the WAGR syndrome.9603434Pollock PM, Spurr N, Bishop T, Newton-Bishop J, Gruis N, van der Velden PA, Goldstein AM, Tucker MA, Foulkes WD, Barnhill R, Haber D, Fountain J, Hayward NKHuman mutationHaplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations. Hum Mutat. 1998; 11(6):424-31.Hum Mutat1998-01-01T00:00:001998Haplotype analysis of two recurrent CDKN2A mutations in 10 melanoma families: evidence for common founders and independent mutations.11159547Arico M, Imashuku S, Clementi R, Hibi S, Teramura T, Danesino C, Haber DA, Nichols KEBloodHemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene. Blood. 2001 Feb 15; 97(4):1131-3.Blood2001-02-15T00:00:002001Hemophagocytic lymphohistiocytosis due to germline mutations in SH2D1A, the X-linked lymphoproliferative disease gene.11432721Ellisen LW, Palmer RE, Maki RG, Truong VB, Tamayo P, Oliner JD, Haber DAEuropean journal of cell biologyCascades of transcriptional induction during human lymphocyte activation. Eur J Cell Biol. 2001 May; 80(5):321-8.Eur J Cell Biol2001-05-01T00:00:002001Cascades of transcriptional induction during human lymphocyte activation.12628187Yajnik V, Paulding C, Sordella R, McClatchey AI, Saito M, Wahrer DC, Reynolds P, Bell DW, Lake R, van den Heuvel S, Settleman J, Haber DACellDOCK4, a GTPase activator, is disrupted during tumorigenesis. Cell. 2003 Mar 07; 112(5):673-84.Cell2003-03-07T00:00:002003DOCK4, a GTPase activator, is disrupted during tumorigenesis.12793891Varley J, Haber DABreast cancer research : BCRFamilial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk. Breast Cancer Res. 2003; 5(3):123-5.Breast Cancer Res2003-02-20T00:00:002003Familial breast cancer and the hCHK2 1100delC mutation: assessing cancer risk.15200961Zhang H, Christoforou A, Aravind L, Emmons SW, van den Heuvel S, Haber DAMolecular cellThe C. elegans Polycomb gene SOP-2 encodes an RNA binding protein. Mol Cell. 2004 Jun 18; 14(6):841-7.Mol Cell2004-06-18T00:00:002004The C. elegans Polycomb gene SOP-2 encodes an RNA binding protein.15542428Sgroi DC, Haber DA, Ryan PD, Ma XJ, Erlander MGCancer cellRE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 2004 Nov; 6(5):445.Cancer Cell2004-11-01T00:00:002004RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.16857818Sequist LV, Joshi VA, Jänne PA, Bell DW, Fidias P, Lindeman NI, Louis DN, Lee JC, Mark EJ, Longtine J, Verlander P, Kucherlapati R, Meyerson M, Haber DA, Johnson BE, Lynch TJClinical cancer research : an official journal of the American Association for Cancer ResearchEpidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4403s-4408s.Clin Cancer Res2006-07-15T00:00:002006Epidermal growth factor receptor mutation testing in the care of lung cancer patients.18458038Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJJournal of clinical oncology : official journal of the American Society of Clinical OncologyFirst-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008 May 20; 26(15):2442-9.J Clin Oncol2008-05-05T00:00:002008First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.18797466Kim S, Mohapatra G, Haber DABritish journal of cancerIn vitro phosphorylation of BRCA2 by the checkpoint kinase CHEK2. Br J Cancer. 2008 Oct 21; 99(8):1302-6.Br J Cancer2008-09-16T00:00:002008In vitro phosphorylation of BRCA2 by the checkpoint kinase CHEK2.21300848Yu M, Stott S, Toner M, Maheswaran S, Haber DAThe Journal of cell biologyCirculating tumor cells: approaches to isolation and characterization. J Cell Biol. 2011 Feb 07; 192(3):373-82.J Cell Biol2011-02-07T00:00:002011Circulating tumor cells: approaches to isolation and characterization.21571217Moisan A, Rivera MN, Lotinun S, Akhavanfard S, Coffman EJ, Cook EB, Stoykova S, Mukherjee S, Schoonmaker JA, Burger A, Kim WJ, Kronenberg HM, Baron R, Haber DA, Bardeesy NDevelopmental cellThe WTX tumor suppressor regulates mesenchymal progenitor cell fate specification. Dev Cell. 2011 May 17; 20(5):583-596.Dev Cell2011-05-17T00:00:002011The WTX tumor suppressor regulates mesenchymal progenitor cell fate specification.D025721Chemicals & Drugs791790.906806WT1 ProteinsAuthorship 1165815D009396Disorders1383640.784371Wilms TumorAuthorship 1137467Authorship 12374811D016162Genes & Molecular Sequences36940.963463Genes, Wilms TumorAuthorship 124478D009360Anatomy3569090.591918Neoplastic Cells, CirculatingMGH Cancer Center ResearchD025521Chemicals & Drugs110728450.461561Tumor Suppressor ProteinsAuthorship 11987614GeneticsMedicinePathologySurgeryHematology/OncologyOncologyDana-Farber Cancer InstituteHarvard Medical SchoolMassachusetts General HospitalSSP1ShivPillaiShiv S. Pillai, M.D., Ph.D.42.37730000000000-71.052500000000007602Pillai, ShivProfessor of MedicineAL118AliceLanAlice Lan, Ph.D.42.37730000000000-71.0525000000000075877Lan, AliceInstructor in Medicine11249selected publications5.318890.00273105883research areas6.393640.00729728130coauthor of95.312230.180160similar toTS23ToshihiroShiodaToshihiro Shioda, M.D., Ph.D.42.37730000000000-71.0525000000000081538Shioda, ToshihiroAssociate Professor of MedicineNJD1NicholasDysonNicholas John Dyson, Ph.D.42.37730000000000-71.052500000000005607Dyson, NicholasProfessor of MedicineLVS1LeciaSequistLecia Vandam Sequist, M.D.42.36239000000000-71.0693169000000028331Sequist, LeciaLandry Family Professor of Medicine in the Field of Medical OncologyTKC6ToniChoueiriToni K. Choueiri, M.D.42.33789600000000-71.1072493000000077491Choueiri, ToniJerome and Nancy Kohlberg Professor of MedicineAB15AndreBernardsAndre Bernards, Ph.D.42.37730000000000-71.0525000000000010942Bernards, AndreCorresponding Member of the Faculty of MedicineMT2MehmetTonerMehmet Toner, Ph.D.42.37904200000000-71.051481000000003525Toner, MehmetHelen Andrus Benedict Professor of SurgeryBW17BenWittnerBen Wittner, Ph.D.42.36125700000000-71.0655270000000061379Wittner, BenInstructor in MedicineAuthorship 1529674MNR1MiguelRiveraMiguel Nicolas Rivera, M.D.42.37730000000000-71.0525000000000060452Rivera, MiguelAssociate Professor of PathologySM9ShyamalaMaheswaranShyamala Maheswaran, Ph.D.42.37730000000000-71.0525000000000010138Maheswaran, ShyamalaProfessor of SurgeryNP7NorbertPerrimonNorbert Perrimon, Ph.D.42.33837200000000-71.103269000000006247Perrimon, NorbertJames Stillman Professor of Developmental BiologyAuthorship 129155132002-12-31HABER, DANIEL A.1993-01-01FUNCTIONAL PROPERTIES OF THE WILMS TUMOR GENE WT1R01CA0585962006-01-31HABER, DANIEL A.2000-02-29FUNCTIONAL CHARACTERIZATION OF BRCA1R01CA0840662012-12-31HABER, DANIEL A.1993-01-01Functional Properties of the Wilms'Tumor Gene WT1R37CA0585962000-03-31HABER, DANIEL A.1995-04-01ISOLATION OF GENE FOR X-LINKED LYMPHOPROLIFERATIONR01CA0640882023-03-31HABER, DANIEL A.2007-07-01Modeling Metastasis and Acquired Drug Resistance Using Circulating Tumor CellsR01CA1299331991-07-31HABER, DANIEL A.1988-08-01MULTIDRUG RESISTANCE GENES--EXPRESSION AND FUNCTIONK08CA0013562003-07-31HABER, DANIEL A.2000-08-01MUTATIONAL ANALYSIS OF P53 RELATED GENESR21CA0876912008-01-31HABER, DANIEL A.2002-02-01Targets of Ewing Sarcoma-Wilms Tumor 1 OncoproteinR01CA090627Co-Principal InvestigatorCo-Principal InvestigatorCo-Principal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorPrincipal InvestigatorAuthorship 1338679Authorship 1381263Authorship 11116213true1Associate Professor of MedicineAssociate Professor of Medicinetrue1Kurt J. Isselbacher Professor of OncologyKurt J. Isselbacher Professor of Oncologytrue1Landry Family Professor of Medicine in the Field of Medical OncologyLandry Family Professor of Medicine in the Field of Medical Oncologytrue1Professor of MedicineProfessor of Medicinetrue1Jerome and Nancy Kohlberg Professor of MedicineJerome and Nancy Kohlberg Professor of Medicinetrue1Instructor in MedicineInstructor in Medicinetrue1James Stillman Professor of Developmental BiologyJames Stillman Professor of Developmental Biologytrue1Instructor in MedicineInstructor in MedicineAuthorship 13359719Authorship 1268191Authorship 16049012Authorship 1293369Authorship 16919314Authorship 1601336Authorship 1630616Authorship 1352193Authorship 1761126true1Associate Professor of PathologyAssociate Professor of PathologyAuthorship 16214928true1Corresponding Member of the Faculty of MedicineCorresponding Member of the Faculty of Medicinetrue1Professor of SurgeryProfessor of SurgeryAuthorship 2174698Authorship 1950371Authorship 2069024Authorship 138294132025-12-31HABER, DANIEL A.;MAHESWARAN, SHYAMALA ;TONER, MEHMET2021-01-08High-flow microfluidics of leukapheresis blood products for functional analysis of breast circulating tumor cellsR01CA255602Co-Principal InvestigatorAuthorship 15957415Authorship 1984367Authorship 16318822026-07-31HABER, DANIEL A.;MAHESWARAN, SHYAMALA ;TONER, MEHMET2021-08-01Microfluidic sorting of lung cancer cells from leukapheresis product as an alternative to metastatic tumor biopsyR01CA260304Co-Principal InvestigatorAuthorship 1978105Authorship 149046Authorship 15680812Authorship 163597Authorship 1886257Authorship 2258505Authorship 3073401Authorship 3698141Authorship 4266091Authorship 2265224Authorship 2473096Authorship 1723875Authorship 1836272Authorship 3324032true1Professor of MedicineProfessor of Medicinetrue1Helen Andrus Benedict Professor of SurgeryHelen Andrus Benedict Professor of SurgeryAuthorship 49850712Authorship 530314Authorship 5556411Authorship 1559942Authorship 1656784Authorship 23723519Authorship 30308429Authorship 4735554Authorship 3424312Authorship 6530652Authorship 64495916Authorship 6621311023719260Horning SJ, Haber DA, Selig WK, Ivy SP, Roberts SA, Allen JD, Sigal EV, Sawyers CLClinical cancer research : an official journal of the American Association for Cancer ResearchDeveloping standards for breakthrough therapy designation in oncology. Clin Cancer Res. 2013 Aug 15; 19(16):4297-304.Clin Cancer Res2013-05-29T00:00:002013Developing standards for breakthrough therapy designation in oncology.23903755Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, Haber DA, Engelman JAScience translational medicineTORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Sci Transl Med. 2013 Jul 31; 5(196):196ra98.Sci Transl Med2013-07-31T00:00:002013TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.Authorship 53273119Authorship 25860711Authorship 3393752Authorship 2094116Authorship 6934961724249259Akhavanfard S, Vargas SO, Han M, Nitta M, Chang CB, Le LP, Fazlollahi L, Nguyen Q, Ma Y, Cosper A, Dias-Santagata D, Han JY, Bergethon K, Borger DR, Ellisen LW, Pomeroy SL, Haber DA, Iafrate AJ, Rivera MNGenes, chromosomes & cancerInactivation of the tumor suppressor WTX in a subset of pediatric tumors. Genes Chromosomes Cancer. 2014 Jan; 53(1):67-77.Genes Chromosomes Cancer2013-11-05T00:00:002013Inactivation of the tumor suppressor WTX in a subset of pediatric tumors.Authorship 6960311324298054Liu M, Roth A, Yu M, Morris R, Bersani F, Rivera MN, Lu J, Shioda T, Vasudevan S, Ramaswamy S, Maheswaran S, Diederichs S, Haber DAGenes & developmentThe IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis. Genes Dev. 2013 Dec 01; 27(23):2543-8.Genes Dev2013-12-01T00:00:002013The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis.Authorship 3859406Authorship 7002441424360956Javaid S, Zhang J, Anderssen E, Black JC, Wittner BS, Tajima K, Ting DT, Smolen GA, Zubrowski M, Desai R, Maheswaran S, Ramaswamy S, Whetstine JR, Haber DACell reportsDynamic chromatin modification sustains epithelial-mesenchymal transition following inducible expression of Snail-1. Cell Rep. 2013 Dec 26; 5(6):1679-89.Cell Rep2013-12-19T00:00:002013Dynamic chromatin modification sustains epithelial-mesenchymal transition following inducible expression of Snail-1.Authorship 2501876Authorship 2601087Authorship 29867022Authorship 2993511Authorship 2777418Authorship 2751193Authorship 2959518Authorship 3157032Authorship 7230351924577360Karabacak NM, Spuhler PS, Fachin F, Lim EJ, Pai V, Ozkumur E, Martel JM, Kojic N, Smith K, Chen PI, Yang J, Hwang H, Morgan B, Trautwein J, Barber TA, Stott SL, Maheswaran S, Kapur R, Haber DA, Toner MNature protocolsMicrofluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc. 2014 Mar; 9(3):694-710.Nat Protoc2014-02-27T00:00:002014Microfluidic, marker-free isolation of circulating tumor cells from blood samples.Authorship 2313855Authorship 3272419Authorship 2744389Authorship 2911612Authorship 90525Authorship 17058314Authorship 2286093Authorship 7292952024746818Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, McMahon M, Bosenberg MW, Stott SL, Ting DT, Ramaswamy S, Toner M, Fisher DE, Maheswaran S, Haber DACell reportsIsolation and molecular characterization of circulating melanoma cells. Cell Rep. 2014 May 08; 7(3):645-53.Cell Rep2014-04-18T00:00:002014Isolation and molecular characterization of circulating melanoma cells.Authorship 3617687Authorship 740669824311731Burger A, Vasilyev A, Tomar R, Selig MK, Nielsen GP, Peterson RT, Drummond IA, Haber DADisease models & mechanismsA zebrafish model of chordoma initiated by notochord-driven expression of HRASV12. Dis Model Mech. 2014 Jul; 7(7):907-13.Dis Model Mech2013-12-05T00:00:002013A zebrafish model of chordoma initiated by notochord-driven expression of HRASV12.25013076Yu M, Bardia A, Aceto N, Bersani F, Madden MW, Donaldson MC, Desai R, Zhu H, Comaills V, Zheng Z, Wittner BS, Stojanov P, Brachtel E, Sgroi D, Kapur R, Shioda T, Ting DT, Ramaswamy S, Getz G, Iafrate AJ, Benes C, Toner M, Maheswaran S, Haber DAScience (New York, N.Y.)Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014 Jul 11; 345(6193):216-20.Science2014-07-11T00:00:002014Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility.Authorship 3338376Authorship 35225813Authorship 74244424Authorship 74423515Authorship 744473124801577Haber DA, Velculescu VECancer discoveryBlood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014 Jun; 4(6):650-61.Cancer Discov2014-05-06T00:00:002014Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA.25032649Nahed BV, Sullivan JP, Madden MW, Oliveira SM, Chi AS, Springer S, Wakimoto H, Bhere D, Shah A, Spuhler P, Batchelor T, Louis DN, Toner M, Maheswaran S, Haber DANeurosurgeryAmerican brain tumor association young investigator award 198 circulating tumor cells in patients with glioblastoma. Neurosurgery. 2014 Aug; 61 Suppl 1:226.Neurosurgery2014-08-01T00:00:002014American brain tumor association young investigator award 198 circulating tumor cells in patients with glioblastoma.Authorship 37936416Authorship 40365718Authorship 42141915Authorship 31194123Authorship 3379609Authorship 3527892Authorship 4454711225139148Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, Chi AS, Wakimoto H, Rothenberg SM, Sequist LV, Kapur R, Shah K, Iafrate AJ, Curry WT, Loeffler JS, Batchelor TT, Louis DN, Toner M, Maheswaran S, Haber DACancer discoveryBrain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov. 2014 Nov; 4(11):1299-309.Cancer Discov2014-08-19T00:00:002014Brain tumor cells in circulation are enriched for mesenchymal gene expression.25129619Wong IY, Javaid S, Wong EA, Perk S, Haber DA, Toner M, Irimia DNature materialsCollective and individual migration following the epithelial-mesenchymal transition. Nat Mater. 2014 Nov; 13(11):1063-71.Nat Mater2014-08-17T00:00:002014Collective and individual migration following the epithelial-mesenchymal transition.Authorship 4191085Authorship 7544131925171411Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, Yu M, Pely A, Engstrom A, Zhu H, Brannigan BW, Kapur R, Stott SL, Shioda T, Ramaswamy S, Ting DT, Lin CP, Toner M, Haber DA, Maheswaran SCellCirculating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014 Aug 28; 158(5):1110-1122.Cell2014-08-28T00:00:002014Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis.Authorship 538814625242334Ting DT, Wittner BS, Ligorio M, Vincent Jordan N, Shah AM, Miyamoto DT, Aceto N, Bersani F, Brannigan BW, Xega K, Ciciliano JC, Zhu H, MacKenzie OC, Trautwein J, Arora KS, Shahid M, Ellis HL, Qu N, Bardeesy N, Rivera MN, Deshpande V, Ferrone CR, Kapur R, Ramaswamy S, Shioda T, Toner M, Maheswaran S, Haber DACell reportsSingle-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. Cell Rep. 2014 Sep 25; 8(6):1905-1918.Cell Rep2014-09-18T00:00:002014Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells.Authorship 75980428Authorship 3741061Authorship 4164110Authorship 4375361Authorship 4507514Authorship 7656502Authorship 766516525024075Bardia A, Haber DAJournal of clinical oncology : official journal of the American Society of Clinical OncologySolidifying liquid biopsies: can circulating tumor cell monitoring guide treatment selection in breast cancer? J Clin Oncol. 2014 Nov 01; 32(31):3470-1.J Clin Oncol2014-07-14T00:00:002014Solidifying liquid biopsies: can circulating tumor cell monitoring guide treatment selection in breast cancer?Authorship 90312Authorship 76804020Authorship 7692161125374341Choy E, Butrynski JE, Harmon DC, Morgan JA, George S, Wagner AJ, D'Adamo D, Cote GM, Flamand Y, Benes CH, Haber DA, Baselga JM, Demetri GDBMC cancerPhase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014 Nov 05; 14:813.BMC Cancer2014-11-05T00:00:002014Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.Authorship 367937925504881Liu Y, Asnani A, Zou L, Bentley VL, Yu M, Wang Y, Dellaire G, Sarkar KS, Dai M, Chen HH, Sosnovik DE, Shin JT, Haber DA, Berman JN, Chao W, Peterson RTScience translational medicineVisnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. Sci Transl Med. 2014 Dec 10; 6(266):266ra170.Sci Transl Med2014-12-10T00:00:002014Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase.Authorship 4689365Authorship 478461125339351Bersani F, Lee J, Yu M, Morris R, Desai R, Ramaswamy S, Toner M, Haber DA, Parekkadan BCancer researchBioengineered implantable scaffolds as a tool to study stromal-derived factors in metastatic cancer models. Cancer Res. 2014 Dec 15; 74(24):7229-38.Cancer Res2014-10-22T00:00:002014Bioengineered implantable scaffolds as a tool to study stromal-derived factors in metastatic cancer models.Authorship 4897713Authorship 510145925593184Flynn RL, Cox KE, Jeitany M, Wakimoto H, Bryll AR, Ganem NJ, Bersani F, Pineda JR, Suvà ML, Benes CH, Haber DA, Boussin FD, Zou LScience (New York, N.Y.)Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors. Science. 2015 Jan 16; 347(6219):273-7.Science2015-01-16T00:00:002015Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors.Authorship 3116663Authorship 3183171Authorship 560699225640006Reátegui E, Aceto N, Lim EJ, Sullivan JP, Jensen AE, Zeinali M, Martel JM, Aranyosi AJ, Li W, Castleberry S, Bardia A, Sequist LV, Haber DA, Maheswaran S, Hammond PT, Toner M, Stott SLAdvanced materials (Deerfield Beach, Fla.)Tunable nanostructured coating for the capture and selective release of viable circulating tumor cells. Adv Mater. 2015 Mar 04; 27(9):1593-9.Adv Mater2015-01-15T00:00:002015Tunable nanostructured coating for the capture and selective release of viable circulating tumor cells.Authorship 3799311Authorship 3916971Authorship 42083118Authorship 4412016Authorship 3564004Authorship 36179613Authorship 27135824Authorship 3987783Authorship 57470410Authorship 4025577Authorship 23290421Authorship 614732Authorship 43431511Authorship 4406092Authorship 557916Authorship 951527Authorship 2487793Authorship 1050702Authorship 11113012Authorship 3213731Authorship 3498439Authorship 35011716Authorship 35096018Authorship 2709135Authorship 29020622Authorship 316952Authorship 3546641Authorship 4273166Authorship 27973011Authorship 3339921425984697Sarioglu AF, Aceto N, Kojic N, Donaldson MC, Zeinali M, Hamza B, Engstrom A, Zhu H, Sundaresan TK, Miyamoto DT, Luo X, Bardia A, Wittner BS, Ramaswamy S, Shioda T, Ting DT, Stott SL, Kapur R, Maheswaran S, Haber DA, Toner MNature methodsA microfluidic device for label-free, physical capture of circulating tumor cell clusters. Nat Methods. 2015 Jul; 12(7):685-91.Nat Methods2015-05-18T00:00:002015A microfluidic device for label-free, physical capture of circulating tumor cell clusters.Authorship 43392913Authorship 4770533Authorship 4935192Authorship 260816Authorship 594505Authorship 3563015Authorship 40646217Authorship 414633Authorship 2398765Authorship 2703019Authorship 3993368Authorship 2833913Authorship 235101Authorship 3601201Authorship 4217757Authorship 5626433Authorship 3450871Authorship 41246911Authorship 4216652Authorship 5173215Authorship 558435725678598Javaid S, Zhang J, Smolen GA, Yu M, Wittner BS, Singh A, Arora KS, Madden MW, Desai R, Zubrowski MJ, Schott BJ, Ting DT, Stott SL, Toner M, Maheswaran S, Shioda T, Ramaswamy S, Haber DAMolecular cancer research : MCRMAPK7 Regulates EMT Features and Modulates the Generation of CTCs. Mol Cancer Res. 2015 May; 13(5):934-43.Mol Cancer Res2015-02-12T00:00:002015MAPK7 Regulates EMT Features and Modulates the Generation of CTCs.25882849Kim WJ, Wittner BS, Amzallag A, Brannigan BW, Ting DT, Ramaswamy S, Maheswaran S, Haber DAThe Journal of biological chemistryThe WTX Tumor Suppressor Interacts with the Transcriptional Corepressor TRIM28. J Biol Chem. 2015 Jun 05; 290(23):14381-90.J Biol Chem2015-04-16T00:00:002015The WTX Tumor Suppressor Interacts with the Transcriptional Corepressor TRIM28.25686219Rothenberg SM, Concannon K, Cullen S, Boulay G, Turke AB, Faber AC, Lockerman EL, Rivera MN, Engelman JA, Maheswaran S, Haber DAeLifeInhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways. Elife. 2015 Feb 16; 4.Elife2015-02-16T00:00:002015Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways.26061253Martel JM, Smith KC, Dlamini M, Pletcher K, Yang J, Karabacak M, Haber DA, Kapur R, Toner MScientific reportsContinuous Flow Microfluidic Bioparticle Concentrator. Sci Rep. 2015 Jun 10; 5:11300.Sci Rep2015-06-10T00:00:002015Continuous Flow Microfluidic Bioparticle Concentrator.Authorship 9619150Authorship 240212Authorship 24380310Authorship 2483374Authorship 2503306Authorship 28386315Authorship 2661241Authorship 3929371Authorship 4023437Authorship 4858421Authorship 3875841126093786Kojic N, Miloševic M, Petrovic D, Isailovic V, Sarioglu AF, Haber DA, Kojic M, Toner MComputers in biology and medicineA computational study of circulating large tumor cells traversing microvessels. Comput Biol Med. 2015 Aug; 63:187-95.Comput Biol Med2015-06-10T00:00:002015A computational study of circulating large tumor cells traversing microvessels.Authorship 2993061Authorship 332808426142780Li W, Reátegui E, Park MH, Castleberry S, Deng JZ, Hsu B, Mayner S, Jensen AE, Sequist LV, Maheswaran S, Haber DA, Toner M, Stott SL, Hammond PTBiomaterialsBiodegradable nano-films for capture and non-invasive release of circulating tumor cells. Biomaterials. 2015 Oct; 65:93-102.Biomaterials2015-06-20T00:00:002015Biodegradable nano-films for capture and non-invasive release of circulating tumor cells.Authorship 81899520Authorship 8189567Authorship 81873613Authorship 81945711Authorship 8212178Authorship 81917913Authorship 82153811Authorship 8207868Authorship 8207956Authorship 82150718Authorship 38007718Authorship 3852173Authorship 40886012Authorship 82433011Authorship 824172225998619Maheswaran S, Haber DACancer researchEx Vivo Culture of CTCs: An Emerging Resource to Guide Cancer Therapy. Cancer Res. 2015 Jun 15; 75(12):2411-5.Cancer Res2015-05-21T00:00:002015Ex Vivo Culture of CTCs: An Emerging Resource to Guide Cancer Therapy.Authorship 831164226311727Sundaresan TK, Haber DAScience translational medicineDoes molecular monitoring matter in early-stage breast cancer? Sci Transl Med. 2015 Aug 26; 7(302):302fs35.Sci Transl Med2015-08-26T00:00:002015Does molecular monitoring matter in early-stage breast cancer?Authorship 5263881Authorship 8339542326383955Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, Desai R, Fox DB, Brannigan BW, Trautwein J, Arora KS, Desai N, Dahl DM, Sequist LV, Smith MR, Kapur R, Wu CL, Shioda T, Ramaswamy S, Ting DT, Toner M, Maheswaran S, Haber DAScience (New York, N.Y.)RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015 Sep 18; 349(6254):1351-6.Science2015-09-18T00:00:002015RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance.Authorship 663103Authorship 8634820Authorship 8373981526394836Tajima K, Yae T, Javaid S, Tam O, Comaills V, Morris R, Wittner BS, Liu M, Engstrom A, Takahashi F, Black JC, Ramaswamy S, Shioda T, Hammell M, Haber DA, Whetstine JR, Maheswaran SNature communicationsSETD1A modulates cell cycle progression through a miRNA network that regulates p53 target genes. Nat Commun. 2015 Sep 23; 6:8257.Nat Commun2015-09-23T00:00:002015SETD1A modulates cell cycle progression through a miRNA network that regulates p53 target genes.Authorship 366382926461489Friedman AA, Amzallag A, Pruteanu-Malinici I, Baniya S, Cooper ZA, Piris A, Hargreaves L, Igras V, Frederick DT, Lawrence DP, Haber DA, Flaherty KT, Wargo JA, Ramaswamy S, Benes CH, Fisher DEPloS oneLandscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. PLoS One. 2015; 10(10):e0140310.PLoS One2015-10-13T00:00:002015Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment.Authorship 84145911Authorship 4544369Authorship 477983Authorship 848042226560026Maheswaran S, Haber DANatureCell fate: Transition loses its invasive edge. Nature. 2015 Nov 26; 527(7579):452-3.Nature2015-11-11T00:00:002015Cell fate: Transition loses its invasive edge.Authorship 8506731526575630Bersani F, Lee E, Kharchenko PV, Xu AW, Liu M, Xega K, MacKenzie OC, Brannigan BW, Wittner BS, Jung H, Ramaswamy S, Park PJ, Maheswaran S, Ting DT, Haber DAProceedings of the National Academy of Sciences of the United States of AmericaPericentromeric satellite repeat expansions through RNA-derived DNA intermediates in cancer. Proc Natl Acad Sci U S A. 2015 Dec 08; 112(49):15148-53.Proc Natl Acad Sci U S A2015-11-02T00:00:002015Pericentromeric satellite repeat expansions through RNA-derived DNA intermediates in cancer.Authorship 854679226678190Sundaresan TK, Haber DAThe Lancet. OncologyFantastic voyage: the future of cancer diagnostics. Lancet Oncol. 2015 Dec; 16(16):1596-8.Lancet Oncol2015-12-01T00:00:002015Fantastic voyage: the future of cancer diagnostics.Authorship 4380551Authorship 4553199Authorship 53165814Authorship 6765722008-08-22T00:00:002008-05-29T00:00:00An shRNA Screen for Regulators of Epithelial-to-Mesenchymal TransitionSummerAuthorship 86286525Authorship 867349826876805Wong KH, Sandlin RD, Carey TR, Miller KL, Shank AT, Oklu R, Maheswaran S, Haber DA, Irimia D, Stott SL, Toner MScientific reportsThe Role of Physical Stabilization in Whole Blood Preservation. Sci Rep. 2016 Feb 15; 6:21023.Sci Rep2016-02-15T00:00:002016The Role of Physical Stabilization in Whole Blood Preservation.26446944Sundaresan TK, Sequist LV, Heymach JV, Riely GJ, Jänne PA, Koch WH, Sullivan JP, Fox DB, Maher R, Muzikansky A, Webb A, Tran HT, Giri U, Fleisher M, Yu HA, Wei W, Johnson BE, Barber TA, Walsh JR, Engelman JA, Stott SL, Kapur R, Maheswaran S, Toner M, Haber DAClinical cancer research : an official journal of the American Association for Cancer ResearchDetection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. Clin Cancer Res. 2016 Mar 01; 22(5):1103-10.Clin Cancer Res2015-10-07T00:00:002015Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.Authorship 30163314Authorship 3672234Authorship 4017508Authorship 8790591327082874Indolfi L, Ligorio M, Ting DT, Xega K, Tzafriri AR, Bersani F, Aceto N, Thapar V, Fuchs BC, Deshpande V, Baker AB, Ferrone CR, Haber DA, Langer R, Clark JW, Edelman ERBiomaterialsA tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma. Biomaterials. 2016 07; 93:71-82.Biomaterials2016-03-31T00:00:002016A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.Authorship 8804331127091969Au SH, Storey BD, Moore JC, Tang Q, Chen YL, Javaid S, Sarioglu AF, Sullivan R, Madden MW, O'Keefe R, Haber DA, Maheswaran S, Langenau DM, Stott SL, Toner MProceedings of the National Academy of Sciences of the United States of AmericaClusters of circulating tumor cells traverse capillary-sized vessels. Proc Natl Acad Sci U S A. 2016 May 03; 113(18):4947-52.Proc Natl Acad Sci U S A2016-04-18T00:00:002016Clusters of circulating tumor cells traverse capillary-sized vessels.Authorship 4420536Authorship 5340231Authorship 6324051Associate Professor0Full Professor4Instructor5Other FacultyAuthorship 638617Authorship 55976315Authorship 5644811Authorship 8953433327397505Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, Aben N, Gonçalves E, Barthorpe S, Lightfoot H, Cokelaer T, Greninger P, van Dyk E, Chang H, de Silva H, Heyn H, Deng X, Egan RK, Liu Q, Mironenko T, Mitropoulos X, Richardson L, Wang J, Zhang T, Moran S, Sayols S, Soleimani M, Tamborero D, Lopez-Bigas N, Ross-Macdonald P, Esteller M, Gray NS, Haber DA, Stratton MR, Benes CH, Wessels LFA, Saez-Rodriguez J, McDermott U, Garnett MJCellA Landscape of Pharmacogenomic Interactions in Cancer. Cell. 2016 Jul 28; 166(3):740-754.Cell2016-07-07T00:00:002016A Landscape of Pharmacogenomic Interactions in Cancer.Authorship 5047127Authorship 50953262023-08-31HABER, DANIEL A. ;SEQUIST, LECIA V.1997-08-01Training Program in Cancer Biology and TherapeuticsT32CA0713452008-08-31HABER, DANIEL A.2002-09-04Genetic Models of Cellular ProliferationP01CA0952812019-06-30TONER, MEHMET2010-09-30Point-of care Microfluidics for Early Detection of CancerU01EB012493Authorship 6991714Authorship 596981Authorship 6455813Authorship 98645Authorship 36629810Authorship 3777607Authorship 26231016Authorship 263410427926867Comaills V, Kabeche L, Morris R, Buisson R, Yu M, Madden MW, LiCausi JA, Boukhali M, Tajima K, Pan S, Aceto N, Sil S, Zheng Y, Sundaresan T, Yae T, Jordan NV, Miyamoto DT, Ting DT, Ramaswamy S, Haas W, Zou L, Haber DA, Maheswaran SCell reportsGenomic Instability Is Induced by Persistent Proliferation of Cells Undergoing Epithelial-to-Mesenchymal Transition. Cell Rep. 2016 12 06; 17(10):2632-2647.Cell Rep2016-12-06T00:00:002016Genomic Instability Is Induced by Persistent Proliferation of Cells Undergoing Epithelial-to-Mesenchymal Transition.Authorship 3066243Authorship 93959822Authorship 9413312427556950Jordan NV, Bardia A, Wittner BS, Benes C, Ligorio M, Zheng Y, Yu M, Sundaresan TK, Licausi JA, Desai R, O'Keefe RM, Ebright RY, Boukhali M, Sil S, Onozato ML, Iafrate AJ, Kapur R, Sgroi D, Ting DT, Toner M, Ramaswamy S, Haas W, Maheswaran S, Haber DANatureHER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature. 2016 09 01; 537(7618):102-106.Nature2016-08-24T00:00:002016HER2 expression identifies dynamic functional states within circulating breast cancer cells.Authorship 413119Authorship 4432381Authorship 4494299Authorship 4663274Authorship 55695910Authorship 626231Authorship 73244128943350Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C, Haber DA, Licht JD, Sugrue SP, Roberts T, Rangnekar VM, Shi YMolecular and cellular biologyA novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol. 1996 Dec; 16(12):6945-56.Mol Cell Biol1996-12-01T00:00:001996A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1.8898735Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin AK, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes WD, Garber JENature medicineFrequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nat Med. 1996 Nov; 2(11):1179-83.Nat Med1996-11-01T00:00:001996Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families.8827073Haber DA, Englert C, Maheswaran SMedical and pediatric oncologyFunctional properties of WT1. Med Pediatr Oncol. 1996 Nov; 27(5):453-5.Med Pediatr Oncol1996-11-01T00:00:001996Functional properties of WT1.9528864Counter CM, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber DA, Weinberg RAOncogeneTelomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene. 1998 Mar 05; 16(9):1217-22.Oncogene1998-03-05T00:00:001998Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase.10490105Lee SB, Huang K, Palmer R, Truong VB, Herzlinger D, Kolquist KA, Wong J, Paulding C, Yoon SK, Gerald W, Oliner JD, Haber DACellThe Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin. Cell. 1999 Sep 03; 98(5):663-73.Cell1999-09-03T00:00:001999The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin.16857803Kwak EL, Jankowski J, Thayer SP, Lauwers GY, Brannigan BW, Harris PL, Okimoto RA, Haserlat SM, Driscoll DR, Ferry D, Muir B, Settleman J, Fuchs CS, Kulke MH, Ryan DP, Clark JW, Sgroi DC, Haber DA, Bell DWClinical cancer research : an official journal of the American Association for Cancer ResearchEpidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 1):4283-7.Clin Cancer Res2006-07-15T00:00:002006Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.9620558Dahia PL, FitzGerald MG, Zhang X, Marsh DJ, Zheng Z, Pietsch T, von Deimling A, Haluska FG, Haber DA, Eng COncogeneA highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene. 1998 May 07; 16(18):2403-6.Oncogene1998-05-07T00:00:001998A highly conserved processed PTEN pseudogene is located on chromosome band 9p21.11237525Lee SB, Haber DAExperimental cell researchWilms tumor and the WT1 gene. Exp Cell Res. 2001 Mar 10; 264(1):74-99.Exp Cell Res2001-03-10T00:00:002001Wilms tumor and the WT1 gene.11593420Mullan PB, Quinn JE, Gilmore PM, McWilliams S, Andrews H, Gervin C, McCabe N, McKenna S, White P, Song YH, Maheswaran S, Liu E, Haber DA, Johnston PG, Harkin DPOncogeneBRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene. 2001 Sep 27; 20(43):6123-31.Oncogene2001-09-27T00:00:002001BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents.11960373Wong JC, Lee SB, Bell MD, Reynolds PA, Fiore E, Stamenkovic I, Truong V, Oliner JD, Gerald WL, Haber DAOncogeneInduction of the interleukin-2/15 receptor beta-chain by the EWS-WT1 translocation product. Oncogene. 2002 Mar 27; 21(13):2009-19.Oncogene2002-03-27T00:00:002002Induction of the interleukin-2/15 receptor beta-chain by the EWS-WT1 translocation product.10561187Nichols KE, Levitz S, Shannon KE, Wahrer DC, Bell DW, Chang G, Hegde S, Neuberg D, Shafman T, Tarbell NJ, Mauch P, Ishioka C, Haber DA, Diller LJournal of clinical oncology : official journal of the American Society of Clinical OncologyHeterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. J Clin Oncol. 1999 Apr; 17(4):1259.J Clin Oncol1999-04-01T00:00:001999Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease.1651275Pelletier J, Schalling M, Buckler AJ, Rogers A, Haber DA, Housman DGenes & developmentExpression of the Wilms' tumor gene WT1 in the murine urogenital system. Genes Dev. 1991 Aug; 5(8):1345-56.Genes Dev1991-08-01T00:00:001991Expression of the Wilms' tumor gene WT1 in the murine urogenital system.1671709Buckler AJ, Pelletier J, Haber DA, Glaser T, Housman DEMolecular and cellular biologyIsolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development. Mol Cell Biol. 1991 Mar; 11(3):1707-12.Mol Cell Biol1991-03-01T00:00:001991Isolation, characterization, and expression of the murine Wilms' tumor gene (WT1) during kidney development.12923058Reynolds PA, Smolen GA, Palmer RE, Sgroi D, Yajnik V, Gerald WL, Haber DAGenes & developmentIdentification of a DNA-binding site and transcriptional target for the EWS-WT1(+KTS) oncoprotein. Genes Dev. 2003 Sep 01; 17(17):2094-107.Genes Dev2003-08-15T00:00:002003Identification of a DNA-binding site and transcriptional target for the EWS-WT1(+KTS) oncoprotein.16110318Rivera MN, Haber DANature reviews. CancerWilms' tumour: connecting tumorigenesis and organ development in the kidney. Nat Rev Cancer. 2005 Sep; 5(9):699-712.Nat Rev Cancer2005-09-01T00:00:002005Wilms' tumour: connecting tumorigenesis and organ development in the kidney.16258541Bell DW, Gore I, Okimoto RA, Godin-Heymann N, Sordella R, Mulloy R, Sharma SV, Brannigan BW, Mohapatra G, Settleman J, Haber DANature geneticsInherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet. 2005 Dec; 37(12):1315-6.Nat Genet2005-10-30T00:00:002005Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.16869779Haber DA, Bell DW, Sordella R, Kwak EL, Godin-Heymann N, Sharma SV, Lynch TJ, Settleman JCold Spring Harbor symposia on quantitative biologyMolecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb Symp Quant Biol. 2005; 70:419-26.Cold Spring Harb Symp Quant Biol2005-01-01T00:00:002005Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.17204608Rivera MN, Kim WJ, Wells J, Driscoll DR, Brannigan BW, Han M, Kim JC, Feinberg AP, Gerald WL, Vargas SO, Chin L, Iafrate AJ, Bell DW, Haber DAScience (New York, N.Y.)An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science. 2007 Feb 02; 315(5812):642-5.Science2007-01-04T00:00:002007An X chromosome gene, WTX, is commonly inactivated in Wilms tumor.9354795Lee SB, Kolquist KA, Nichols K, Englert C, Maheswaran S, Ladanyi M, Gerald WL, Haber DANature geneticsThe EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour. Nat Genet. 1997 Nov; 17(3):309-13.Nat Genet1997-11-01T00:00:001997The EWS-WT1 translocation product induces PDGFA in desmoplastic small round-cell tumour.9553041Maheswaran S, Englert C, Zheng G, Lee SB, Wong J, Harkin DP, Bean J, Ezzell R, Garvin AJ, McCluskey RT, DeCaprio JA, Haber DAGenes & developmentInhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70. Genes Dev. 1998 Apr 15; 12(8):1108-20.Genes Dev1998-04-15T00:00:001998Inhibition of cellular proliferation by the Wilms tumor suppressor WT1 requires association with the inducible chaperone Hsp70.9949745O'Donnell L, Stueve A, San Doval A, Duran R, Haber D, Atnafou R, Johnson N, Grant U, Murray H, Juhn G, Tang J, Piessens PAmerican journal of public healthThe effectiveness of the Reach for Health Community Youth Service learning program in reducing early and unprotected sex among urban middle school students. Am J Public Health. 1999 Feb; 89(2):176-81.Am J Public Health1999-02-01T00:00:001999The effectiveness of the Reach for Health Community Youth Service learning program in reducing early and unprotected sex among urban middle school students.1681381Grundy P, Telzerow P, Paterson MC, Haber D, Berman B, Li F, Garber JLancet (London, England)Chromosome 11 uniparental isodisomy predisposing to embryonal neoplasms. Lancet. 1991 Oct 26; 338(8774):1079-80.Lancet1991-10-26T00:00:001991Chromosome 11 uniparental isodisomy predisposing to embryonal neoplasms.11719428Lee SB, Kim SH, Bell DW, Wahrer DC, Schiripo TA, Jorczak MM, Sgroi DC, Garber JE, Li FP, Nichols KE, Varley JM, Godwin AK, Shannon KM, Harlow E, Haber DACancer researchDestabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome. Cancer Res. 2001 Nov 15; 61(22):8062-7.Cancer Res2001-11-15T00:00:002001Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome.1658787Haber DA, Sohn RL, Buckler AJ, Pelletier J, Call KM, Housman DEProceedings of the National Academy of Sciences of the United States of AmericaAlternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci U S A. 1991 Nov 01; 88(21):9618-22.Proc Natl Acad Sci U S A1991-11-01T00:00:001991Alternative splicing and genomic structure of the Wilms tumor gene WT1.12791274Zhang H, Azevedo RB, Lints R, Doyle C, Teng Y, Haber D, Emmons SWDevelopmental cellGlobal regulation of Hox gene expression in C. elegans by a SAM domain protein. Dev Cell. 2003 Jun; 4(6):903-15.Dev Cell2003-06-01T00:00:002003Global regulation of Hox gene expression in C. elegans by a SAM domain protein.12968092Ryan PD, Haber DA, Shannon KM, Smith BL, Fan MJThe New England journal of medicineCase records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 28-2003. A 51-year-old premenopausal woman with newly diagnosed breast cancer and a strong family history of breast cancer. N Engl J Med. 2003 Sep 11; 349(11):1076-82.N Engl J Med2003-09-11T00:00:002003Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 28-2003. A 51-year-old premenopausal woman with newly diagnosed breast cancer and a strong family history of breast cancer.1846091Haber DA, Housman DECellRate-limiting steps: the genetics of pediatric cancers. Cell. 1991 Jan 11; 64(1):5-8.Cell1991-01-11T00:00:001991Rate-limiting steps: the genetics of pediatric cancers.11156380Seth P, Lunetta KL, Bell DW, Gray H, Nasser SM, Rhei E, Kaelin CM, Iglehart DJ, Marks JR, Garber JE, Haber DA, Polyak KCancer researchPhenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer. Cancer Res. 2000 Dec 15; 60(24):6859-63.Cancer Res2000-12-15T00:00:002000Phenol sulfotransferases: hormonal regulation, polymorphism, and age of onset of breast cancer.11085597Ino Y, Wahrer DC, Bell DW, Haber DA, Louis DNNeurogeneticsMutation analysis of the hCHK2 gene in primary human malignant gliomas. Neurogenetics. 2000 Sep; 3(1):45-6.Neurogenetics2000-09-01T00:00:002000Mutation analysis of the hCHK2 gene in primary human malignant gliomas.23372014Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, Isakoff SJ, Ciciliano JC, Wells MN, Shah AM, Concannon KF, Donaldson MC, Sequist LV, Brachtel E, Sgroi D, Baselga J, Ramaswamy S, Toner M, Haber DA, Maheswaran SScience (New York, N.Y.)Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013 Feb 01; 339(6119):580-4.Science2013-02-01T00:00:002013Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition.3174438Darzynkiewicz E, Stepinski J, Ekiel I, Jin Y, Haber D, Sijuwade T, Tahara SMNucleic acids researchBeta-globin mRNAs capped with m7G, m2.7(2)G or m2.2.7(3)G differ in intrinsic translation efficiency. Nucleic Acids Res. 1988 Sep 26; 16(18):8953-62.Nucleic Acids Res1988-09-26T00:00:001988Beta-globin mRNAs capped with m7G, m2.7(2)G or m2.2.7(3)G differ in intrinsic translation efficiency.9288757Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA, Weinberg RACellhEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997 Aug 22; 90(4):785-95.Cell1997-08-22T00:00:001997hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization.11027344Chaudhuri S, Cariappa A, Tang M, Bell D, Haber DA, Isselbacher KJ, Finkelstein D, Forcione D, Pillai SProceedings of the National Academy of Sciences of the United States of AmericaGenetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. Proc Natl Acad Sci U S A. 2000 Oct 10; 97(21):11451-4.Proc Natl Acad Sci U S A2000-10-10T00:00:002000Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles.12802034Hariharan IK, Haber DAThe New England journal of medicineYeast, flies, worms, and fish in the study of human disease. N Engl J Med. 2003 Jun 12; 348(24):2457-63.N Engl J Med2003-06-12T00:00:002003Yeast, flies, worms, and fish in the study of human disease.1850845Buckler AJ, Chang DD, Graw SL, Brook JD, Haber DA, Sharp PA, Housman DEProceedings of the National Academy of Sciences of the United States of AmericaExon amplification: a strategy to isolate mammalian genes based on RNA splicing. Proc Natl Acad Sci U S A. 1991 May 01; 88(9):4005-9.Proc Natl Acad Sci U S A1991-05-01T00:00:001991Exon amplification: a strategy to isolate mammalian genes based on RNA splicing.15107848Zhang H, Smolen GA, Palmer R, Christoforou A, van den Heuvel S, Haber DANature geneticsSUMO modification is required for in vivo Hox gene regulation by the Caenorhabditis elegans Polycomb group protein SOP-2. Nat Genet. 2004 May; 36(5):507-11.Nat Genet2004-04-11T00:00:002004SUMO modification is required for in vivo Hox gene regulation by the Caenorhabditis elegans Polycomb group protein SOP-2.9241260Haber D, Harlow ENature geneticsTumour-suppressor genes: evolving definitions in the genomic age. Nat Genet. 1997 Aug; 16(4):320-2.Nat Genet1997-08-01T00:00:001997Tumour-suppressor genes: evolving definitions in the genomic age.9509273Ellisen LW, Haber DAAnnual review of medicineHereditary breast cancer. Annu Rev Med. 1998; 49:425-36.Annu Rev Med1998-01-01T00:00:001998Hereditary breast cancer.9811875Nichols KE, Harkin DP, Levitz S, Krainer M, Kolquist KA, Genovese C, Bernard A, Ferguson M, Zuo L, Snyder E, Buckler AJ, Wise C, Ashley J, Lovett M, Valentine MB, Look AT, Gerald W, Housman DE, Haber DAProceedings of the National Academy of Sciences of the United States of AmericaInactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A. 1998 Nov 10; 95(23):13765-70.Proc Natl Acad Sci U S A1998-11-10T00:00:001998Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome.12024000Haber DThe New England journal of medicineProphylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med. 2002 May 23; 346(21):1660-2.N Engl J Med2002-05-20T00:00:002002Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations.1654525Pelletier J, Bruening W, Li FP, Haber DA, Glaser T, Housman DENatureWT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. Nature. 1991 Oct 03; 353(6343):431-4.Nature1991-10-03T00:00:001991WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour.1313285Haber DA, Buckler AJThe New biologistWT1: a novel tumor suppressor gene inactivated in Wilms' tumor. New Biol. 1992 Feb; 4(2):97-106.New Biol1992-02-01T00:00:001992WT1: a novel tumor suppressor gene inactivated in Wilms' tumor.1346094Haber DABloodMultidrug resistance (MDR 1) in leukemia: is it time to test? Blood. 1992 Jan 15; 79(2):295-8.Blood1992-01-15T00:00:001992Multidrug resistance (MDR 1) in leukemia: is it time to test?18591665Diederichs S, Jung S, Rothenberg SM, Smolen GA, Mlody BG, Haber DAProceedings of the National Academy of Sciences of the United States of AmericaCoexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites. Proc Natl Acad Sci U S A. 2008 Jul 08; 105(27):9284-9.Proc Natl Acad Sci U S A2008-06-30T00:00:002008Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites.10463575Bell DW, Wahrer DC, Kang DH, MacMahon MS, FitzGerald MG, Ishioka C, Isselbacher KJ, Krainer M, Haber DACancer researchCommon nonsense mutations in RAD52. Cancer Res. 1999 Aug 15; 59(16):3883-8.Cancer Res1999-08-15T00:00:001999Common nonsense mutations in RAD52.10550129Haber DAJournal of clinical oncology : official journal of the American Society of Clinical OncologyBreast cancer in carriers of BRCA1 and BRCA2 mutations: tackling a molecular and clinical conundrum. J Clin Oncol. 1999 Nov; 17(11):3367-70.J Clin Oncol1999-11-01T00:00:001999Breast cancer in carriers of BRCA1 and BRCA2 mutations: tackling a molecular and clinical conundrum.10612799Shafman TD, Levitz S, Nixon AJ, Gibans LA, Nichols KE, Bell DW, Ishioka C, Isselbacher KJ, Gelman R, Garber J, Harris JR, Haber DAGenes, chromosomes & cancerPrevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor. Genes Chromosomes Cancer. 2000 Feb; 27(2):124-9.Genes Chromosomes Cancer2000-02-01T00:00:002000Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor.15131400Gal I, Gershoni Baruch R, Haber D, Dagan E, Eisenberg-Barzilai S, Zidan J, Friedman EFamilial cancerThe 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers. Fam Cancer. 2004; 3(1):11-4.Fam Cancer2004-01-01T00:00:002004The 1100delAT BRCA1 and the 8765delAG BRCA2 mutations: occurrence in high-risk non-Ashkenazi Jews and haplotype comparison of Jewish and non-Jewish carriers.15296752Song YH, Mirey G, Betson M, Haber DA, Settleman JCurrent biology : CBThe Drosophila ATM ortholog, dATM, mediates the response to ionizing radiation and to spontaneous DNA damage during development. Curr Biol. 2004 Aug 10; 14(15):1354-9.Curr Biol2004-08-10T00:00:002004The Drosophila ATM ortholog, dATM, mediates the response to ionizing radiation and to spontaneous DNA damage during development.12498718Palmer RE, Lee SB, Wong JC, Reynolds PA, Zhang H, Truong V, Oliner JD, Gerald WL, Haber DACancer cellInduction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumorigenesis. Cancer Cell. 2002 Dec; 2(6):497-505.Cancer Cell2002-12-01T00:00:002002Induction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumorigenesis.15843680Riemenschneider MJ, Bell DW, Haber DA, Louis DNThe New England journal of medicinePulmonary adenocarcinomas with mutant epidermal growth factor receptors. N Engl J Med. 2005 Apr 21; 352(16):1724-5.N Engl J Med2005-04-21T00:00:002005Pulmonary adenocarcinomas with mutant epidermal growth factor receptors.16115901Sequist LV, Haber DA, Lynch TJClinical cancer research : an official journal of the American Association for Cancer ResearchEpidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors. Clin Cancer Res. 2005 Aug 15; 11(16):5668-70.Clin Cancer Res2005-08-15T00:00:002005Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.16857812Lynch TJ, Adjei AA, Bunn PA, Eisen TG, Engelman J, Goss GD, Haber DA, Heymach JV, Jänne PA, Johnson BE, Johnson DH, Lilenbaum RC, Meyerson M, Sandler AB, Sequist LV, Settleman J, Wong KK, Hart CSClinical cancer research : an official journal of the American Association for Cancer ResearchSummary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents. Clin Cancer Res. 2006 Jul 15; 12(14 Pt 2):4365s-4371s.Clin Cancer Res2006-07-15T00:00:002006Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.9108440Englert C, Maheswaran S, Garvin AJ, Kreidberg J, Haber DACancer researchInduction of p21 by the Wilms' tumor suppressor gene WT1. Cancer Res. 1997 Apr 15; 57(8):1429-34.Cancer Res1997-04-15T00:00:001997Induction of p21 by the Wilms' tumor suppressor gene WT1.9145678Krainer M, Silva-Arrieta S, FitzGerald MG, Shimada A, Ishioka C, Kanamaru R, MacDonald DJ, Unsal H, Finkelstein DM, Bowcock A, Isselbacher KJ, Haber DAThe New England journal of medicineDifferential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med. 1997 May 15; 336(20):1416-21.N Engl J Med1997-05-15T00:00:001997Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer.17704304Smolen GA, Schott BJ, Stewart RA, Diederichs S, Muir B, Provencher HL, Look AT, Sgroi DC, Peterson RT, Haber DAGenes & developmentA Rap GTPase interactor, RADIL, mediates migration of neural crest precursors. Genes Dev. 2007 Sep 01; 21(17):2131-6.Genes Dev2007-08-17T00:00:002007A Rap GTPase interactor, RADIL, mediates migration of neural crest precursors.17671201Godin-Heymann N, Bryant I, Rivera MN, Ulkus L, Bell DW, Riese DJ, Settleman J, Haber DACancer researchOncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res. 2007 Aug 01; 67(15):7319-26.Cancer Res2007-08-01T00:00:002007Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation.18596266Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M, Haber DAThe New England journal of medicineDetection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008 Jul 24; 359(4):366-77.N Engl J Med2008-07-02T00:00:002008Detection of mutations in EGFR in circulating lung-cancer cells.2163761Haber DA, Buckler AJ, Glaser T, Call KM, Pelletier J, Sohn RL, Douglass EC, Housman DECellAn internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor. Cell. 1990 Jun 29; 61(7):1257-69.Cell1990-06-29T00:00:001990An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor.17344839Haber DA, Settleman JNatureCancer: drivers and passengers. Nature. 2007 Mar 08; 446(7132):145-6.Nature2007-03-08T00:00:002007Cancer: drivers and passengers.15284455Sordella R, Bell DW, Haber DA, Settleman JScience (New York, N.Y.)Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004 Aug 20; 305(5687):1163-7.Science2004-07-29T00:00:002004Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.1321431Haber DA, Timmers HT, Pelletier J, Sharp PA, Housman DEProceedings of the National Academy of Sciences of the United States of AmericaA dominant mutation in the Wilms tumor gene WT1 cooperates with the viral oncogene E1A in transformation of primary kidney cells. Proc Natl Acad Sci U S A. 1992 Jul 01; 89(13):6010-4.Proc Natl Acad Sci U S A1992-07-01T00:00:001992A dominant mutation in the Wilms tumor gene WT1 cooperates with the viral oncogene E1A in transformation of primary kidney cells.9122215Ishioka C, Suzuki T, FitzGerald M, Krainer M, Shimodaira H, Shimada A, Nomizu T, Isselbacher KJ, Haber D, Kanamaru RProceedings of the National Academy of Sciences of the United States of AmericaDetection of heterozygous truncating mutations in the BRCA1 and APC genes by using a rapid screening assay in yeast. Proc Natl Acad Sci U S A. 1997 Mar 18; 94(6):2449-53.Proc Natl Acad Sci U S A1997-03-18T00:00:001997Detection of heterozygous truncating mutations in the BRCA1 and APC genes by using a rapid screening assay in yeast.19737971Zhang J, Song YH, Brannigan BW, Wahrer DC, Schiripo TA, Harris PL, Haserlat SM, Ulkus LE, Shannon KM, Garber JE, Freedman ML, Henderson BE, Zou L, Sgroi DC, Haber DA, Bell DWMolecular cancer research : MCRPrevalence and functional analysis of sequence variants in the ATR checkpoint mediator Claspin. Mol Cancer Res. 2009 Sep; 7(9):1510-6.Mol Cancer Res2009-09-08T00:00:002009Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator Claspin.8266105Haber DA, Park S, Maheswaran S, Englert C, Re GG, Hazen-Martin DJ, Sens DA, Garvin AJScience (New York, N.Y.)WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant. Science. 1993 Dec 24; 262(5142):2057-9.Science1993-12-24T00:00:001993WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant.8388523Roberts DJ, Haber D, Sklar J, Crum CPLaboratory investigation; a journal of technical methods and pathologyExtrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker. Lab Invest. 1993 May; 68(5):528-36.Lab Invest1993-05-01T00:00:001993Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker.18299447Kim WJ, Okimoto RA, Purton LE, Goodwin M, Haserlat SM, Dayyani F, Sweetser DA, McClatchey AI, Bernard OA, Look AT, Bell DW, Scadden DT, Haber DABloodMutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood. 2008 May 01; 111(9):4716-22.Blood2008-02-25T00:00:002008Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias.18413746Zhang J, Smolen GA, Haber DACancer researchNegative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway. Cancer Res. 2008 Apr 15; 68(8):2789-94.Cancer Res2008-04-15T00:00:002008Negative regulation of YAP by LATS1 underscores evolutionary conservation of the Drosophila Hippo pathway.18711136Rothenberg SM, Engelman JA, Le S, Riese DJ, Haber DA, Settleman JProceedings of the National Academy of Sciences of the United States of AmericaModeling oncogene addiction using RNA interference. Proc Natl Acad Sci U S A. 2008 Aug 26; 105(34):12480-4.Proc Natl Acad Sci U S A2008-08-18T00:00:002008Modeling oncogene addiction using RNA interference.7651738Luo XN, Reddy JC, Yeyati PL, Idris AH, Hosono S, Haber DA, Licht JD, Atweh GFOncogeneThe tumor suppressor gene WT1 inhibits ras-mediated transformation. Oncogene. 1995 Aug 17; 11(4):743-50.Oncogene1995-08-17T00:00:001995The tumor suppressor gene WT1 inhibits ras-mediated transformation.7877656Haber DAThe New England journal of medicineTelomeres, cancer, and immortality. N Engl J Med. 1995 Apr 06; 332(14):955-6.N Engl J Med1995-04-06T00:00:001995Telomeres, cancer, and immortality.16778182Diederichs S, Haber DACancer researchSequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing. Cancer Res. 2006 Jun 15; 66(12):6097-104.Cancer Res2006-06-15T00:00:002006Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing.1325734Haber DA, Housman DEAdvances in cancer researchThe genetics of Wilms' tumor. Adv Cancer Res. 1992; 59:41-68.Adv Cancer Res1992-01-01T00:00:001992The genetics of Wilms' tumor.22042947Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, Salgia R, Bang YJ, Clark JW, Solomon BJ, Iafrate AJJournal of clinical oncology : official journal of the American Society of Clinical OncologyMET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011 Dec 20; 29(36):4803-10.J Clin Oncol2011-10-31T00:00:002011MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib.9890362O'Donnell L, Stueve A, San Doval A, Duran R, Atnafou R, Haber D, Johnson N, Murray H, Grant U, Juhn G, Tang J, Bass J, Piessens PThe Journal of adolescent health : official publication of the Society for Adolescent MedicineViolence prevention and young adolescents' participation in community youth service. J Adolesc Health. 1999 Jan; 24(1):28-37.J Adolesc Health1999-01-01T00:00:001999Violence prevention and young adolescents' participation in community youth service.10902618Haber DLancet (London, England)BRCA1: an emerging role in the cellular response to DNA damage. Lancet. 2000 Jun 17; 355(9221):2090-1.Lancet2000-06-17T00:00:002000BRCA1: an emerging role in the cellular response to DNA damage.19416806Rivera MN, Kim WJ, Wells J, Stone A, Burger A, Coffman EJ, Zhang J, Haber DAProceedings of the National Academy of Sciences of the United States of AmericaThe tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity. Proc Natl Acad Sci U S A. 2009 May 19; 106(20):8338-43.Proc Natl Acad Sci U S A2009-05-04T00:00:002009The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity.23552373Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, Yu M, Chen PI, Morgan B, Trautwein J, Kimura A, Sengupta S, Stott SL, Karabacak NM, Barber TA, Walsh JR, Smith K, Spuhler PS, Sullivan JP, Lee RJ, Ting DT, Luo X, Shaw AT, Bardia A, Sequist LV, Louis DN, Maheswaran S, Kapur R, Haber DA, Toner MScience translational medicineInertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med. 2013 Apr 03; 5(179):179ra47.Sci Transl Med2013-04-03T00:00:002013Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells.7519872Weremowicz S, Kozakewich HP, Haber D, Park S, Morton CC, Fletcher JAGenes, chromosomes & cancerIdentification of genetically aberrant cell lineages in Wilms' tumors. Genes Chromosomes Cancer. 1994 May; 10(1):40-8.Genes Chromosomes Cancer1994-05-01T00:00:001994Identification of genetically aberrant cell lineages in Wilms' tumors.7553624Nichols KE, Re GG, Yan YX, Garvin AJ, Haber DACancer researchWT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells. Cancer Res. 1995 Oct 15; 55(20):4540-3.Cancer Res1995-10-15T00:00:001995WT1 induces expression of insulin-like growth factor 2 in Wilms' tumor cells.10535733Celli J, Duijf P, Hamel BC, Bamshad M, Kramer B, Smits AP, Newbury-Ecob R, Hennekam RC, Van Buggenhout G, van Haeringen A, Woods CG, van Essen AJ, de Waal R, Vriend G, Haber DA, Yang A, McKeon F, Brunner HG, van Bokhoven HCellHeterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome. Cell. 1999 Oct 15; 99(2):143-53.Cell1999-10-15T00:00:001999Heterozygous germline mutations in the p53 homolog p63 are the cause of EEC syndrome.11087889Haber DThe New England journal of medicineRoads leading to breast cancer. N Engl J Med. 2000 Nov 23; 343(21):1566-8.N Engl J Med2000-11-23T00:00:002000Roads leading to breast cancer.11296223Ellisen LW, Carlesso N, Cheng T, Scadden DT, Haber DAThe EMBO journalThe Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J. 2001 Apr 17; 20(8):1897-909.EMBO J2001-04-17T00:00:002001The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells.1655633Schwartz CE, Haber DA, Stanton VP, Strong LC, Skolnick MH, Housman DEGenomicsFamilial predisposition to Wilms tumor does not segregate with the WT1 gene. Genomics. 1991 Aug; 10(4):927-30.Genomics1991-08-01T00:00:001991Familial predisposition to Wilms tumor does not segregate with the WT1 gene.16027046Lorenzen JA, Bonacci BB, Palmer RE, Wells C, Zhang J, Haber DA, Goldstein AM, Mayer ANGene expression patterns : GEPRbm19 is a nucleolar protein expressed in crypt/progenitor cells of the intestinal epithelium. Gene Expr Patterns. 2005 Dec; 6(1):45-56.Gene Expr Patterns2005-07-18T00:00:002005Rbm19 is a nucleolar protein expressed in crypt/progenitor cells of the intestinal epithelium.149 13th StreetMassachusetts General HospitalMGH Cancer Center, CNY7149 13th StreetCharlestown02129MA18451166McDermott U, Iafrate AJ, Gray NS, Shioda T, Classon M, Maheswaran S, Zhou W, Choi HG, Smith SL, Dowell L, Ulkus LE, Kuhlmann G, Greninger P, Christensen JG, Haber DA, Settleman JCancer researchGenomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res. 2008 May 01; 68(9):3389-95.Cancer Res2008-05-01T00:00:002008Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.2471060Croop JM, Raymond M, Haber D, Devault A, Arceci RJ, Gros P, Housman DEMolecular and cellular biologyThe three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues. Mol Cell Biol. 1989 Mar; 9(3):1346-50.Mol Cell Biol1989-03-01T00:00:001989The three mouse multidrug resistance (mdr) genes are expressed in a tissue-specific manner in normal mouse tissues.19247082Sequist LV, Nagrath S, Toner M, Haber DA, Lynch TJJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerThe CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol. 2009 Mar; 4(3):281-3.J Thorac Oncol2009-03-01T00:00:002009The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients.19935651Zhang J, Ji JY, Yu M, Overholtzer M, Smolen GA, Wang R, Brugge JS, Dyson NJ, Haber DANature cell biologyYAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol. 2009 Dec; 11(12):1444-50.Nat Cell Biol2009-11-22T00:00:002009YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway.20571064Wells J, Rivera MN, Kim WJ, Starbuck K, Haber DAMolecular cancer research : MCRThe predominant WT1 isoform (+KTS) encodes a DNA-binding protein targeting the planar cell polarity gene Scribble in renal podocytes. Mol Cancer Res. 2010 Jul; 8(7):975-85.Mol Cancer Res2010-06-22T00:00:002010The predominant WT1 isoform (+KTS) encodes a DNA-binding protein targeting the planar cell polarity gene Scribble in renal podocytes.8710906FitzGerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, O'Neill E, Koh J, Finkelstein DM, Isselbacher KJ, Sober AJ, Haber DAProceedings of the National Academy of Sciences of the United States of AmericaPrevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci U S A. 1996 Aug 06; 93(16):8541-5.Proc Natl Acad Sci U S A1996-08-06T00:00:001996Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population.10367887Harkin DP, Bean JM, Miklos D, Song YH, Truong VB, Englert C, Christians FC, Ellisen LW, Maheswaran S, Oliner JD, Haber DACellInduction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1. Cell. 1999 May 28; 97(5):575-86.Cell1999-05-28T00:00:001999Induction of GADD45 and JNK/SAPK-dependent apoptosis following inducible expression of BRCA1.10932214Daniels GH, Haber DANature medicineWill radioiodine be useful in treatment of breast cancer? Nat Med. 2000 Aug; 6(8):859-60.Nat Med2000-08-01T00:00:002000Will radioiodine be useful in treatment of breast cancer?1851548Cowell JK, Wadey RB, Haber DA, Call KM, Housman DE, Pritchard JOncogeneStructural rearrangements of the WT1 gene in Wilms' tumour cells. Oncogene. 1991 Apr; 6(4):595-9.Oncogene1991-04-01T00:00:001991Structural rearrangements of the WT1 gene in Wilms' tumour cells.15520190Smolen GA, Vassileva MT, Wells J, Matunis MJ, Haber DACancer researchSUMO-1 modification of the Wilms' tumor suppressor WT1. Cancer Res. 2004 Nov 01; 64(21):7846-51.Cancer Res2004-11-01T00:00:002004SUMO-1 modification of the Wilms' tumor suppressor WT1.15897464Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, Harris PL, Driscoll DR, Fidias P, Lynch TJ, Rabindran SK, McGinnis JP, Wissner A, Sharma SV, Isselbacher KJ, Settleman J, Haber DAProceedings of the National Academy of Sciences of the United States of AmericaIrreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A. 2005 May 24; 102(21):7665-70.Proc Natl Acad Sci U S A2005-05-16T00:00:002005Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.15970680Haber DA, Settleman JCell cycle (Georgetown, Tex.)Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class. Cell Cycle. 2005 Aug; 4(8):1057-9.Cell Cycle2005-08-26T00:00:002005Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class.17290067Sequist LV, Bell DW, Lynch TJ, Haber DAJournal of clinical oncology : official journal of the American Society of Clinical OncologyMolecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol. 2007 Feb 10; 25(5):587-95.J Clin Oncol2007-02-10T00:00:002007Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.11717330Ravenel JD, Broman KW, Perlman EJ, Niemitz EL, Jayawardena TM, Bell DW, Haber DA, Uejima H, Feinberg APJournal of the National Cancer InstituteLoss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst. 2001 Nov 21; 93(22):1698-703.J Natl Cancer Inst2001-11-21T00:00:002001Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor.11719225Palmer RE, Kotsianti A, Cadman B, Boyd T, Gerald W, Haber DACurrent biology : CBWT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin. Curr Biol. 2001 Nov 13; 11(22):1805-9.Curr Biol2001-11-13T00:00:002001WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin.12019146Bell DW, Erban J, Sgroi DC, Haber DACancer researchSelective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2. Cancer Res. 2002 May 15; 62(10):2741-3.Cancer Res2002-05-15T00:00:002002Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2.17287723Erkko H, Xia B, Nikkilä J, Schleutker J, Syrjäkoski K, Mannermaa A, Kallioniemi A, Pylkäs K, Karppinen SM, Rapakko K, Miron A, Sheng Q, Li G, Mattila H, Bell DW, Haber DA, Grip M, Reiman M, Jukkola-Vuorinen A, Mustonen A, Kere J, Aaltonen LA, Kosma VM, Kataja V, Soini Y, Drapkin RI, Livingston DM, Winqvist RNatureA recurrent mutation in PALB2 in Finnish cancer families. Nature. 2007 Mar 15; 446(7133):316-9.Nature2007-02-07T00:00:002007A recurrent mutation in PALB2 in Finnish cancer families.21233348Ting DT, Lipson D, Paul S, Brannigan BW, Akhavanfard S, Coffman EJ, Contino G, Deshpande V, Iafrate AJ, Letovsky S, Rivera MN, Bardeesy N, Maheswaran S, Haber DAScience (New York, N.Y.)Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science. 2011 Feb 04; 331(6017):593-6.Science2011-01-13T00:00:002011Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers.22414137Shah AM, Yu M, Nakamura Z, Ciciliano J, Ulman M, Kotz K, Stott SL, Maheswaran S, Haber DA, Toner MAnalytical chemistryBiopolymer system for cell recovery from microfluidic cell capture devices. Anal Chem. 2012 Apr 17; 84(8):3682-8.Anal Chem2012-04-03T00:00:002012Biopolymer system for cell recovery from microfluidic cell capture devices.23553848Lee RJ, Saylor PJ, Michaelson MD, Rothenberg SM, Smas ME, Miyamoto DT, Gurski CA, Xie W, Maheswaran S, Haber DA, Goldin JG, Smith MRClinical cancer research : an official journal of the American Association for Cancer ResearchA dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res. 2013 Jun 01; 19(11):3088-94.Clin Cancer Res2013-04-03T00:00:002013A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases.15826834Gerald WL, Haber DASeminars in cancer biologyThe EWS-WT1 gene fusion in desmoplastic small round cell tumor. Semin Cancer Biol. 2005 Jun; 15(3):197-205.Semin Cancer Biol2005-06-01T00:00:002005The EWS-WT1 gene fusion in desmoplastic small round cell tumor.16461907Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, Christensen JG, Settleman J, Haber DAProceedings of the National Academy of Sciences of the United States of AmericaAmplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A. 2006 Feb 14; 103(7):2316-21.Proc Natl Acad Sci U S A2006-02-06T00:00:002006Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752.18097410Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis UJ, Tompkins RG, Haber DA, Toner MNatureIsolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007 Dec 20; 450(7173):1235-9.Nature2007-12-20T00:00:002007Isolation of rare circulating tumour cells in cancer patients by microchip technology.7326744Haber DA, Schimke RTCellUnstable amplification of an altered dihydrofolate reductase gene associated with double-minute chromosomes. Cell. 1981 Nov; 26(3 Pt 1):355-62.Cell1981-11-01T00:00:001981Unstable amplification of an altered dihydrofolate reductase gene associated with double-minute chromosomes.16299242Cohen EE, Lingen MW, Martin LE, Harris PL, Brannigan BW, Haserlat SM, Okimoto RA, Sgroi DC, Dahiya S, Muir B, Clark JR, Rocco JW, Vokes EE, Haber DA, Bell DWClinical cancer research : an official journal of the American Association for Cancer ResearchResponse of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR. Clin Cancer Res. 2005 Nov 15; 11(22):8105-8.Clin Cancer Res2005-11-15T00:00:002005Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.8389468Maheswaran S, Park S, Bernard A, Morris JF, Rauscher FJ, Hill DE, Haber DAProceedings of the National Academy of Sciences of the United States of AmericaPhysical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci U S A. 1993 Jun 01; 90(11):5100-4.Proc Natl Acad Sci U S A1993-06-01T00:00:001993Physical and functional interaction between WT1 and p53 proteins.8618823Englert C, Vidal M, Maheswaran S, Ge Y, Ezzell RM, Isselbacher KJ, Haber DAProceedings of the National Academy of Sciences of the United States of AmericaTruncated WT1 mutants alter the subnuclear localization of the wild-type protein. Proc Natl Acad Sci U S A. 1995 Dec 19; 92(26):11960-4.Proc Natl Acad Sci U S A1995-12-19T00:00:001995Truncated WT1 mutants alter the subnuclear localization of the wild-type protein.17332364Mulloy R, Ferrand A, Kim Y, Sordella R, Bell DW, Haber DA, Anderson KS, Settleman JCancer researchEpidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib. Cancer Res. 2007 Mar 01; 67(5):2325-30.Cancer Res2007-03-01T00:00:002007Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.21062900Smolen GA, Zhang J, Zubrowski MJ, Edelman EJ, Luo B, Yu M, Ng LW, Scherber CM, Schott BJ, Ramaswamy S, Irimia D, Root DE, Haber DAGenes & developmentA genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migration. Genes Dev. 2010 Dec 01; 24(23):2654-65.Genes Dev2010-11-09T00:00:002010A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migration.19366796McDermott U, Ames RY, Iafrate AJ, Maheswaran S, Stubbs H, Greninger P, McCutcheon K, Milano R, Tam A, Lee DY, Lucien L, Brannigan BW, Ulkus LE, Ma XJ, Erlander MG, Haber DA, Sharma SV, Settleman JCancer researchLigand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res. 2009 May 01; 69(9):3937-46.Cancer Res2009-04-14T00:00:002009Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.7738027Reddy JC, Morris JC, Wang J, English MA, Haber DA, Shi Y, Licht JDThe Journal of biological chemistryWT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins. J Biol Chem. 1995 May 05; 270(18):10878-84.J Biol Chem1995-05-05T00:00:001995WT1-mediated transcriptional activation is inhibited by dominant negative mutant proteins.8298644Park S, Bernard A, Bove KE, Sens DA, Hazen-Martin DJ, Garvin AJ, Haber DANature geneticsInactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour. Nat Genet. 1993 Dec; 5(4):363-7.Nat Genet1993-12-01T00:00:001993Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.22763454Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, Ciciliano JC, Smas ME, Winokur D, Gilman AJ, Ulman MJ, Xega K, Contino G, Alagesan B, Brannigan BW, Milos PM, Ryan DP, Sequist LV, Bardeesy N, Ramaswamy S, Toner M, Maheswaran S, Haber DANatureRNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature. 2012 Jul 26; 487(7408):510-3.Nature2012-07-26T00:00:002012RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis.3285479Haber DA, Mayer RJSeminars in oncologyPrimary gastrointestinal lymphoma. Semin Oncol. 1988 Apr; 15(2):154-69.Semin Oncol1988-04-01T00:00:001988Primary gastrointestinal lymphoma.8531968FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein DM, Beer-Romero P, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, Mayzel KA, Isselbacher KJ, Friend SH, Haber DAThe New England journal of medicineGerm-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med. 1996 Jan 18; 334(3):143-9.N Engl J Med1996-01-18T00:00:001996Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer.20300105Sharma SV, Haber DA, Settleman JNature reviews. CancerCell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer. 2010 Apr; 10(4):241-53.Nat Rev Cancer2010-03-19T00:00:002010Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents.Authorship 10196889043868Lamartine J, Nichols KE, Yin L, Krainer M, Heitzmann F, Bernard A, Gaudi S, Lenoir GM, Sullivan JL, Ikeda JE, Porta G, Schlessinger D, Romeo G, Haber DA, Sylla BS, Harkin DPEuropean journal of human genetics : EJHGPhysical map and cosmid contig encompassing a new interstitial deletion of the X-linked lymphoproliferative syndrome region. Eur J Hum Genet. 1996; 4(6):342-51.Eur J Hum Genet1996-01-01T00:00:001996Physical map and cosmid contig encompassing a new interstitial deletion of the X-linked lymphoproliferative syndrome region.9054948FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, Finkelstein DM, Isselbacher KJ, Haber DANature geneticsHeterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet. 1997 Mar; 15(3):307-10.Nat Genet1997-03-01T00:00:001997Heterozygous ATM mutations do not contribute to early onset of breast cancer.9620778Kolquist KA, Ellisen LW, Counter CM, Meyerson M, Tan LK, Weinberg RA, Haber DA, Gerald WLNature geneticsExpression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet. 1998 Jun; 19(2):182-6.Nat Genet1998-06-01T00:00:001998Expression of TERT in early premalignant lesions and a subset of cells in normal tissues.9572485Maheswaran S, Englert C, Lee SB, Ezzel RM, Settleman J, Haber DAOncogeneE1B 55K sequesters WT1 along with p53 within a cytoplasmic body in adenovirus-transformed kidney cells. Oncogene. 1998 Apr 23; 16(16):2041-50.Oncogene1998-04-23T00:00:001998E1B 55K sequesters WT1 along with p53 within a cytoplasmic body in adenovirus-transformed kidney cells.9715274FitzGerald MG, Marsh DJ, Wahrer D, Bell D, Caron S, Shannon KE, Ishioka C, Isselbacher KJ, Garber JE, Eng C, Haber DAOncogeneGermline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer. Oncogene. 1998 Aug 13; 17(6):727-31.Oncogene1998-08-13T00:00:001998Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer.1322241Haber DA, Housman DECancer surveysRole of the WT1 gene in Wilms' tumour. Cancer Surv. 1992; 12:105-17.Cancer Surv1992-01-01T00:00:001992Role of the WT1 gene in Wilms' tumour.13678594Zhang H, Palmer R, Gao X, Kreidberg J, Gerald W, Hsiao L, Jensen RV, Gullans SR, Haber DACurrent biology : CBTranscriptional activation of placental growth factor by the forkhead/winged helix transcription factor FoxD1. Curr Biol. 2003 Sep 16; 13(18):1625-9.Curr Biol2003-09-16T00:00:002003Transcriptional activation of placental growth factor by the forkhead/winged helix transcription factor FoxD1.15913747Kwak EL, Moberg KH, Wahrer DC, Quinn JE, Gilmore PM, Graham CA, Hariharan IK, Harkin DP, Haber DA, Bell DWGynecologic oncologyInfrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer. Gynecol Oncol. 2005 Jul; 98(1):124-8.Gynecol Oncol2005-07-01T00:00:002005Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer.16204011Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DAJournal of clinical oncology : official journal of the American Society of Clinical OncologyEpidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005 Nov 01; 23(31):8081-92.J Clin Oncol2005-10-03T00:00:002005Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.23123854Mitra D, Luo X, Morgan A, Wang J, Hoang MP, Lo J, Guerrero CR, Lennerz JK, Mihm MC, Wargo JA, Robinson KC, Devi SP, Vanover JC, D'Orazio JA, McMahon M, Bosenberg MW, Haigis KM, Haber DA, Wang Y, Fisher DENatureAn ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background. Nature. 2012 Nov 15; 491(7424):449-53.Nature2012-10-31T00:00:002012An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background.9393847Haber DACellSplicing into senescence: the curious case of p16 and p19ARF. Cell. 1997 Nov 28; 91(5):555-8.Cell1997-11-28T00:00:001997Splicing into senescence: the curious case of p16 and p19ARF.9606360Haber DA, Fearon ERLancet (London, England)The promise of cancer genetics. Lancet. 1998 May; 351 Suppl 2:SII1-8.Lancet1998-05-01T00:00:001998The promise of cancer genetics.11565033Moberg KH, Bell DW, Wahrer DC, Haber DA, Hariharan IKNatureArchipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature. 2001 Sep 20; 413(6853):311-6.Nature2001-09-20T00:00:002001Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines.